Merck Unveils Strong Q2 Performance

1 August 2010 (Last Updated August 1st, 2010 18:30)

Merck has announced its financial results for the second quarter of 2010, reporting earnings-per-share of $0.86. Worldwide sales for the company stood at $11.3bn, amounting to net income of $752m. The company benefited from strong performances from its brands including Ja

Merck has announced its financial results for the second quarter of 2010, reporting earnings-per-share of $0.86.

Worldwide sales for the company stood at $11.3bn, amounting to net income of $752m.

The company benefited from strong performances from its brands including Januvia, Janumet, Remicade, Isentress and Temodar, while Animal Health and Merck Consumer Care produced strong global sales.

Merck chairman and CEO Richard T Clark said that the company had put on a strong performance since executing their post-merger strategy, having previously merged with Schering-Plough.